ESR1 is a predictive biomarker for use of anastrozole, exemestane, and letrozole in patients.

Breast carcinoma has the most therapies with ESR1 as a predictive biomarker.

Of the therapies with ESR1 as a predictive biomarker, 0 are FDA-approved in at least one clinical setting and 0 have NCCN guidelines in at least one clinical setting.

ESR1 D538G, ESR1 E380Q, ESR1 L536H, ESR1 L536P, and ESR1 L536Q are the top alterations on ESR1 targeted by therapies [4].

ESR1 status serves as an inclusion eligibility criteria in 9 clinical trials, of which 8 are open and 1 is closed. Of the trials that contain ESR1 status as an inclusion criterion, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), 6 are phase 2 (6 open), and 1 is phase 3 (1 open).

Trials with ESR1 status in the inclusion eligibility criteria most commonly target breast carcinoma and breast adenocarcinoma [4].

The most frequent alterations to serve as inclusion eligibility criteria are ESR1 Mutation, ESR1 D538G, ESR1 S463P, ESR1 Y537C, and ESR1 Y537N [4].

Fulvestrant, abemaciclib, lasofoxifene, tamoxifen, and azd9833 are the most frequent therapies in trials with ESR1 as an inclusion criteria [4].